Optimizing the Clinical Outcomes of Patients With Immune Thrombocytopenia is organized by i3 Health.
Release: November 6, 2019
Expiration: November 5, 2020
Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with ITP.
i3 Health designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity.
Immune thrombocytopenia (ITP) is a heterogeneous disorder with variable clinical features that range from asymptomatic thrombocytopenia to bothersome bruising to life-threatening intracranial hemorrhage. The lack of specific diagnostic criteria remains an important unmet need. Bleeding events are the most common clinical manifestation of ITP but are unpredictable with current laboratory testing. Many patients do not exhibit significant bleeding even in the setting of severe thrombocytopenia.
While bleeding is an indication for treatment, clinical management is often influenced by other considerations, including tolerability of therapy, comorbidities with a predisposition to bleeding, the need for interventions that may cause bleeding, complications of specific therapies, accessibility of care, and patient factors (eg, worry or anxiety about disease burden, activity level, lifestyle). For this reason, the goals of therapy and/or efficacy measures of treatment response can vary significantly between patients.
Upon completion of this activity, participants should be able to:
• Discuss the pathogenesis of ITP and mechanisms of therapeutic strategies
• Differentiate the efficacy and safety profiles of current and emerging ITP therapies
• Assess supportive care strategies that can be used to help patients with ITP achieve their goals of therapy
Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.
Haematopathology, Internal Medicine, Haematology, Internal Medicine and General Medicine